Citius Oncology, Inc.

NASDAQ:CTOR

Drug Manufacturers - General

Healthcare
$0.56 +4.23%

+$0.03 today

Market cap
$51.83M
Beta
3.42
P/E (TTM)
-1.6
EPS (TTM)
-$0.42
52W Low $0.49High $6.19

Volume 0.15M

Average 0.12M

CTOR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Citius Oncology, Inc.NASDAQ: CTOR

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 100.03M shares rose 39.8% year over year, ahead of the +20.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 14.4% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +39.8% holds above the trailing-twelve-month pace of +20.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.03M+14.4% QoQ
Last fiscal yearSep 2025
73.27M+2.4% YoY
LTMMar 2026
85M+20.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.8%——
1 year+2.4%——
3-year CAGR-6.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
73.27M USD
Year-over-year change
+2.4%
3-year CAGR
-6.7%

Weighted Avg Shares (Diluted) vs competitors

How CTOR compares with its peers on the latest reported figures

  • CTOR's LTM Mar 2026 weighted avg shares (diluted) of 85M shares is the 4th highest of the 10 companies compared; the peer median is 21.96M shares.
  • Its year-over-year change of +20.9% is the 5th highest of 10, against a peer median of +12.5%.
  • Over three fiscal years its annual growth of -6.7% compares with a peer median of +18.0%.
CTOR Competitors Peer median
Weighted Avg Shares (Diluted) for CTOR and competitors
Company Period LTM YoY 3-year CAGR
OWLTOwlet, Inc.LTM Mar 2026149.39M +1085.6%+313.6%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
FBRXForte Biosciences, Inc.LTM Mar 202688.77M +1552.7%+496.0%
CTORCitius Oncology, Inc.LTM Mar 202685M +20.9%-6.7%
SPROSpero Therapeutics, Inc.LTM Mar 202657.24M +5.3%+16.2%
ACTUActuate Therapeutics IncLTM Mar 202621.96M +12.5%+11.8%
LNSRLENSAR, Inc.LTM Mar 202612.87M +10.8%+5.6%
SCLXScilex Holding CompanyLTM Mar 202610.28M +60.8%+42.2%
MCRBSeres Therapeutics, Inc.LTM Mar 20268.99M +10.4%+18.0%
VORVor Biopharma Inc.LTM Mar 20265.81M +40.8%+70.9%
Peer median (excluding CTOR) 21.96M+12.5%+18.0%

Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development6.86M4.24M4.93M6.42M
Selling, General & Admin2.86M7.88M15.65M17.1M
Operating Expenses9.71M12.12M20.57M23.52M
Depreciation & Amortization9.71M000
EBITDA0(12.12M)(20.57M)(23.49M)
EBITDA Margin————
Operating Income(9.71M)(12.12M)(20.57M)(23.52M)
Operating Margin————
Interest Income00036.37K
Interest Expense000218.03K
Other Income / Expenses000(181.66K)
Income Before Tax(9.71M)(12.12M)(20.57M)(23.7M)
Pre-Tax Margin————
Income Tax Expense1.15M576K576K1.06M
Net Income(10.87M)(12.7M)(21.15M)(24.76M)
Net Margin————
EPS (Basic)(0.08)(0.19)(0.30)(0.34)
EPS (Diluted)(0.08)(0.19)(0.30)(0.34)
Weighted Avg Shares90.16M89.48M71.55M73.27M
Weighted Avg Shares (Diluted)90.16M89.48M71.55M73.27M

Citius Oncology, Inc.

NASDAQ:CTOR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.